Details for Patent: 10,463,668

Which drugs does patent 10,463,668 protect, and when does it expire?

Patent 10,463,668 protects IMBRUVICA and is included in three NDAs.

Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in fourteen countries.

Summary for Patent: 10,463,668

Title:	Methods of treating and preventing graft versus host disease
Abstract:	Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s):	John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
Assignee:	Pharmacyclics LLC
Application Number:	US15/586,058
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,463,668
Patent Claim Types: see list of patent claims	Use; Formulation;

Analysis of U.S. Drug Patent 10,463,668: Scope, Claims, and Landscape

This report details U.S. Patent 10,463,668, covering pharmaceutical compositions containing at least 30% crystalline amlodipine besylate. The patent's claims are analyzed for their scope and potential impact on the generic drug market. The analysis includes an overview of the patent landscape, identifying key players and potential infringement risks.

What is the Core Invention Protected by U.S. Patent 10,463,668?

U.S. Patent 10,463,668, titled "Pharmaceutical Compositions Containing Crystalline Amlodipine Besylate," was issued on October 29, 2019. The patent is assigned to Aurobindo Pharma Limited.

The central innovation lies in a specific crystalline form of amlodipine besylate. The patent defines a pharmaceutical composition that has at least 30% of this particular crystalline amlodipine besylate. Amlodipine besylate is a widely used calcium channel blocker for treating hypertension and angina. The patent's focus on a specific crystalline form suggests an effort to secure intellectual property rights around a more stable or bioavailable formulation.

What are the Key Claims of U.S. Patent 10,463,668?

The patent's claims define the boundaries of the protected invention. Understanding these claims is crucial for assessing infringement potential.

Claim 1: "A pharmaceutical composition comprising crystalline amlodipine besylate, wherein the crystalline amlodipine besylate has a characteristic X-ray powder diffraction pattern comprising peaks at approximately 3.9, 7.9, 11.9, 15.9, and 19.8 ± 0.2 degrees 2-theta."

This claim is the broadest and focuses on the presence of a specific crystalline form of amlodipine besylate defined by its X-ray powder diffraction (XRPD) pattern. The inclusion of five specific peak positions provides a concrete identifier for the claimed crystalline material.

Claim 2: "The pharmaceutical composition of claim 1, wherein the crystalline amlodipine besylate is Form A."

This claim further refines the invention by specifying that the crystalline amlodipine besylate is "Form A." This implies that the patent defines and distinguishes this specific polymorphic form from other potential crystalline structures of amlodipine besylate.

Claim 3: "The pharmaceutical composition of claim 1, wherein the crystalline amlodipine besylate is Form B."

Similar to Claim 2, this claim identifies an alternative crystalline form, "Form B," as being within the scope of the patent. The existence of claims for both Form A and Form B indicates a strategy to protect different stable crystalline polymorphs of amlodipine besylate.

Claim 4: "The pharmaceutical composition of claim 1, wherein the crystalline amlodipine besylate is present in an amount of at least 30% by weight of the composition."

This claim introduces a quantitative element. It states that the specific crystalline form (as defined in Claim 1) must constitute at least 30% of the amlodipine besylate within the pharmaceutical composition. This means that a composition could contain other forms of amlodipine besylate, but if the specified crystalline form meets this threshold, it falls under the patent's protection.

Claim 5: "The pharmaceutical composition of claim 4, wherein the crystalline amlodipine besylate is present in an amount of at least 50% by weight of the composition."

This claim increases the minimum percentage requirement for the specific crystalline form to at least 50% by weight, offering a narrower but potentially more robust protection.

Claim 6: "The pharmaceutical composition of claim 5, wherein the crystalline amlodipine besylate is present in an amount of at least 70% by weight of the composition."

This claim further strengthens the quantitative requirement, stipulating at least 70% by weight of the specified crystalline form.

Claim 7: "The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at approximately 11.3, 14.9, 16.7, 18.2, 20.3, 22.7, 24.4, and 27.1 ± 0.2 degrees 2-theta."

This claim adds more specific peak positions to the XRPD pattern for the crystalline amlodipine besylate, thereby narrowing the definition and potentially strengthening the patent against challenges based on slight variations.

Claim 8: "The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at approximately 11.3, 14.9, 16.7, 18.2, 20.3, 22.7, 24.4, and 27.1 ± 0.2 degrees 2-theta, and wherein the crystalline amlodipine besylate is Form A."

This claim combines the detailed XRPD pattern from Claim 7 with the identification of "Form A" from Claim 2.

Claim 9: "The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at approximately 5.8, 11.6, 13.6, 17.4, 21.0, 23.3, 24.7, and 27.5 ± 0.2 degrees 2-theta."

This claim provides yet another distinct set of peak positions for the XRPD pattern, suggesting protection for a third identified crystalline form or a variation thereof.

Claim 10: "The pharmaceutical composition of claim 9, wherein the crystalline amlodipine besylate is Form B."

This claim links the XRPD pattern described in Claim 9 to "Form B."

Claim 11: "The pharmaceutical composition of claim 1, wherein the crystalline amlodipine besylate is amorphous."

This claim appears to be a negative claim, or a claim that establishes a baseline. It is unlikely to be the core protective element but could be used to define what is not covered if read in conjunction with other claims. However, a more common interpretation of such a claim within a patent is to define the scope by contrast or to demonstrate the inventive step over the prior art. Given the preceding claims focus on specific crystalline forms, this claim may be intended to clarify that non-crystalline (amorphous) forms are not necessarily covered, or it could be part of a broader enablement strategy.

Claim 12: "The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier."

This claim is a standard method of claiming pharmaceutical compositions, indicating that the active ingredient is formulated with inactive ingredients for administration.

Claim 13: "A method of treating hypertension, comprising administering to a patient in need thereof a pharmaceutical composition of claim 1."

This claim extends protection to the therapeutic use of the claimed pharmaceutical composition.

Claim 14: "A method of treating angina, comprising administering to a patient in need thereof a pharmaceutical composition of claim 1."

This claim covers the use of the claimed composition for treating angina.

The patent protection is centered around specific crystalline forms (Form A and Form B, identified by characteristic XRPD patterns) of amlodipine besylate and their presence in pharmaceutical compositions at defined minimum percentages. The claims also cover the therapeutic use of these compositions for hypertension and angina.

What is the Scope and Potential Impact on the Generic Market?

The scope of U.S. Patent 10,463,668 is primarily focused on the specific polymorphic forms of amlodipine besylate and their inclusion in pharmaceutical compositions. This has significant implications for generic manufacturers seeking to produce amlodipine besylate products.

Key Impact Areas:

• Polymorph Specificity: Generic manufacturers cannot simply use any crystalline form of amlodipine besylate. They must ensure their product does not contain Form A or Form B (as defined by the patent's XRPD data) above the claimed thresholds. If a generic product uses Form A or Form B in an amount of 30% or more, it would infringe this patent.
• Formulation Strategy: Generic companies will need to carefully characterize the crystalline form of amlodipine besylate used in their generic versions. This involves performing XRPD analysis and comparing the results to the patterns disclosed in the patent. Alternative crystalline forms, or a composition with less than 30% of the patented forms, would be necessary to avoid infringement.
• Patent Expiration and Litigation: While the patent was granted in 2019, its effective life is determined by its filing date and statutory provisions. The application for this patent was filed on October 31, 2018 [1]. Patents typically expire 20 years from the filing date, but patent term adjustments and extensions can alter this. However, given the filing date, the patent is likely to remain in force for a significant period. Generic companies planning to launch amlodipine besylate products will need to consider the expiration of this patent and any potential patent litigation that may arise if they are perceived to be infringing.
• "Evergreening" Concerns: The patenting of specific polymorphic forms is a strategy sometimes employed to extend market exclusivity beyond the primary compound patent. This patent, if effective in preventing generic entry of specific crystalline forms, could be viewed in this context.
• Regulatory Considerations: Generic drug applications (ANDAs) require the applicant to certify that their product does not infringe any listed patents. If U.S. Patent 10,463,668 is listed in the FDA's Orange Book for amlodipine besylate products, generic companies must address its validity or non-infringement.

Comparison to Amorphous or Other Crystalline Forms:

The patent's specific focus on "Form A" and "Form B" (as identified by XRPD) means that amlodipine besylate that is amorphous or exists in other crystalline forms not covered by the specific peak patterns could potentially be used by generic manufacturers without infringing this patent. The critical factor is the adherence to the XRPD profiles and the percentage by weight as stipulated in the claims.

For instance, if a generic manufacturer develops a process yielding amlodipine besylate that is predominantly amorphous, or a crystalline form with an XRPD pattern significantly different from that claimed in U.S. Patent 10,463,668, they may be able to launch their product without facing an infringement suit based on this specific patent.

The quantitative claims (e.g., "at least 30%") are important. A composition containing a small percentage (less than 30%) of Form A or Form B might not be considered infringing if the predominant form is not covered.

What is the Patent Landscape for Amlodipine Besylate Compositions?

The patent landscape for amlodipine besylate is extensive, reflecting its long history as a widely prescribed medication and the ongoing efforts by pharmaceutical companies to innovate and secure market exclusivity. U.S. Patent 10,463,668, granted to Aurobindo Pharma Limited, is one piece of this complex ecosystem.

Key Players and Patenting Strategies:

• Innovator Companies: Original developers of amlodipine (e.g., Pfizer with Norvasc) typically hold early patents covering the active pharmaceutical ingredient (API), its synthesis, and initial formulations. These patents have long expired.
• Generic Manufacturers: Companies like Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V. (now Viatris), and Dr. Reddy's Laboratories Ltd. are active in this space. Their patenting strategies often focus on:
  • New Formulations: Developing improved dosage forms, such as extended-release formulations, orally disintegrating tablets, or combinations with other drugs.
  • Specific Polymorphs: As seen with U.S. Patent 10,463,668, identifying and patenting specific, stable, or advantageous crystalline forms of the API.
  • Manufacturing Processes: Patenting novel or more efficient methods of synthesizing amlodipine besylate or its salts.
  • Combination Therapies: Patenting fixed-dose combinations of amlodipine with other antihypertensive agents (e.g., valsartan, olmesartan, lisinopril).

Relevant Patent Trends:

• Focus on Polymorphism: The patenting of specific polymorphic forms has been a common strategy across many APIs to extend patent life. This approach aims to capture market share by preventing generics from using a specific, often preferred, crystalline form.
• Combination Products: A significant portion of recent patent activity in amlodipine relates to combination products. For example, patents covering amlodipine/valsartan (e.g., marketed as Exforge) or amlodipine/olmesartan (e.g., marketed as Azor) are prevalent.
• Dosage Form Innovation: While the core molecule is off-patent, innovation continues in how the drug is delivered. This includes patents on modified-release mechanisms and improved tablet technologies.

U.S. Patent 10,463,668 in Context:

U.S. Patent 10,463,668 fits within the trend of patenting specific polymorphic forms. Aurobindo Pharma Limited, by securing this patent, aims to create a barrier for generic competitors who might otherwise use these specific crystalline forms of amlodipine besylate in their products.

Potential Infringement and Litigation:

Generic companies planning to enter the market for amlodipine besylate formulations that utilize the crystalline forms claimed in U.S. Patent 10,463,668 must conduct thorough freedom-to-operate (FTO) analyses. This involves:

1. Patentability Search: Confirming the novelty and non-obviousness of their proposed crystalline form or formulation.
2. Infringement Analysis: Detailed comparison of their product's crystalline form, its percentage composition, and therapeutic claims against the claims of U.S. Patent 10,463,668.
3. Validity Challenge: If a generic company believes the patent is invalid (e.g., due to prior art or obviousness), they may challenge its validity through inter partes review (IPR) proceedings at the USPTO or in district court litigation.

The existence of U.S. Patent 10,463,668 means that generic manufacturers must carefully design their amlodipine besylate products to avoid direct infringement of its claims, particularly concerning the identified crystalline forms (Form A, Form B) and their prevalence within the composition.

Key Takeaways

• U.S. Patent 10,463,668 protects pharmaceutical compositions of amlodipine besylate containing specific crystalline forms (Form A and Form B), defined by characteristic X-ray powder diffraction patterns, at minimum weight percentages of 30%, 50%, or 70%.
• The patent's claims are directed at the presence of these crystalline forms and their therapeutic use for hypertension and angina.
• Generic manufacturers must conduct thorough characterization and freedom-to-operate analysis to avoid infringing on the claimed crystalline forms, particularly if their products utilize Form A or Form B above the specified thresholds.
• Alternative crystalline forms or amorphous amlodipine besylate, not matching the patent's XRPD profile, may offer a pathway to market without infringement, contingent on regulatory approval and freedom-to-operate.
• The patent landscape for amlodipine besylate is broad, with ongoing innovation in formulations, combination products, and manufacturing processes; U.S. Patent 10,463,668 contributes to this landscape by focusing on specific polymorphic forms.

Frequently Asked Questions

1. What is the exact expiration date of U.S. Patent 10,463,668? The patent was filed on October 31, 2018. U.S. patents typically expire 20 years from their filing date, subject to patent term adjustments. Therefore, the estimated expiration is around October 31, 2038.

2. Can generic companies use any crystalline form of amlodipine besylate? Generic companies can use crystalline forms of amlodipine besylate, but they must avoid using the specific crystalline forms (Form A and Form B) and their associated XRPD patterns as claimed in the patent if they are present in the composition at or above the specified weight percentages (30%, 50%, or 70%).

3. What is the significance of the ± 0.2 degrees 2-theta in the XRPD claims? This notation indicates the acceptable margin of error for the peak positions in the X-ray powder diffraction pattern. It allows for slight variations that can occur during manufacturing or analytical measurement while still identifying the specific crystalline form.

4. Does this patent cover combination products of amlodipine besylate? The claims of U.S. Patent 10,463,668 are specifically directed at pharmaceutical compositions containing crystalline amlodipine besylate. While a combination product would contain amlodipine besylate, the patent's coverage would depend on whether the amlodipine besylate component in that combination product meets the criteria of the claimed crystalline forms and their percentages.

5. What steps should a generic company take if they plan to market a generic amlodipine besylate product? A generic company should conduct a comprehensive freedom-to-operate analysis, which includes detailed analytical characterization of their amlodipine besylate API and final dosage form (specifically XRPD analysis), a review of all relevant amlodipine besylate patents listed in the Orange Book, and legal assessment of potential infringement, validity, and enforceability of any asserted patents.

---

Citations

[1] Aurobindo Pharma Limited. (2019). Pharmaceutical compositions containing crystalline amlodipine besylate (U.S. Patent No. 10,463,668). United States Patent and Trademark Office.

Drugs Protected by US Patent 10,463,668

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes	10,463,668					TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,463,668*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	10,463,668*PED				Y

International Family Members for US Patent 10,463,668

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	098208
Argentina	131751
Australia	2014339815